Glaucoma is one of the leading causes of blindness and visual impairment, affecting around 80 million patients worldwide. It’s also one of the most common neurodegenerative diseases. Currently, the only approved way to manage glaucoma is through lowering pressure in the eye, but these treatments don’t work for everyone, and they don’t address the neurodegeneration that is a hallmark of the disease. That’s why recent research has investigated the potential therapeutic effects of something called ‘nicotinamide’ (otherwise known as NAM; a form of vitamin B3 that’s found in the diet or supplements). We will be joined by Professor Ted Garway-Heath from UCL, and Associate Professor Gerassimos Lascaratos, who have been funded by Fight for Sight for their work on glaucoma.

Too book: Webinar Registration – Zoom